26
|
Aguilar M, Cavasonza LA, Ambrosi G, Arruda L, Attig N, Barao F, Barrin L, Bartoloni A, Başeğmez-du Pree S, Battiston R, Behlmann M, Beranek B, Berdugo J, Bertucci B, Bindi V, Bollweg K, Borgia B, Boschini MJ, Bourquin M, Bueno EF, Burger J, Burger WJ, Burmeister S, Cai XD, Capell M, Casaus J, Castellini G, Cervelli F, Chang YH, Chen GM, Chen GR, Chen HS, Chen Y, Cheng L, Chou HY, Chouridou S, Choutko V, Chung CH, Clark C, Coignet G, Consolandi C, Contin A, Corti C, Cui Z, Dadzie K, Dass A, Delgado C, Della Torre S, Demirköz MB, Derome L, Di Falco S, Di Felice V, Díaz C, Dimiccoli F, von Doetinchem P, Dong F, Donnini F, Duranti M, Egorov A, Eline A, Feng J, Fiandrini E, Fisher P, Formato V, Freeman C, Gámez C, García-López RJ, Gargiulo C, Gast H, Gervasi M, Giovacchini F, Gómez-Coral DM, Gong J, Goy C, Grabski V, Grandi D, Graziani M, Haino S, Han KC, Hashmani RK, He ZH, Heber B, Hsieh TH, Hu JY, Incagli M, Jang WY, Jia Y, Jinchi H, Karagöz G, Khiali B, Kim GN, Kirn T, Konyushikhin M, Kounina O, Kounine A, Koutsenko V, Krasnopevtsev D, Kuhlman A, Kulemzin A, La Vacca G, Laudi E, Laurenti G, Lazzizzera I, Lebedev A, Lee HT, Lee SC, Li JQ, Li M, Li Q, Li S, Li JH, Li ZH, Liang J, Light C, Lin CH, Lippert T, Liu JH, Liu Z, Lu SQ, Lu YS, Luebelsmeyer K, Luo JZ, Luo X, Machate F, Mañá C, Marín J, Marquardt J, Martin T, Martínez G, Masi N, Maurin D, Medvedeva T, Menchaca-Rocha A, Meng Q, Mikhailov VV, Molero M, Mott P, Mussolin L, Negrete J, Nikonov N, Nozzoli F, Oliva A, Orcinha M, Palermo M, Palmonari F, Paniccia M, Pashnin A, Pauluzzi M, Pensotti S, Phan HD, Plyaskin V, Pohl M, Poluianov S, Qin X, Qu ZY, Quadrani L, Rancoita PG, Rapin D, Conde AR, Robyn E, Rosier-Lees S, Rozhkov A, Rozza D, Sagdeev R, Schael S, von Dratzig AS, Schwering G, Seo ES, Shakfa Z, Shan BS, Siedenburg T, Solano C, Song JW, Song XJ, Sonnabend R, Strigari L, Su T, Sun Q, Sun ZT, Tacconi M, Tang XW, Tang ZC, Tian J, Ting SCC, Ting SM, Tomassetti N, Torsti J, Urban T, Usoskin I, Vagelli V, Vainio R, Valencia-Otero M, Valente E, Valtonen E, Vázquez Acosta M, Vecchi M, Velasco M, Vialle JP, Wang CX, Wang L, Wang LQ, Wang NH, Wang QL, Wang S, Wang X, Wang Y, Wang ZM, Wei J, Weng ZL, Wu H, Xiong RQ, Xu W, Yan Q, Yang Y, Yashin II, Yi H, Yu YM, Yu ZQ, Zannoni M, Zhang C, Zhang F, Zhang FZ, Zhang JH, Zhang Z, Zhao F, Zheng C, Zheng ZM, Zhuang HL, Zhukov V, Zichichi A, Zuccon P. Periodicities in the Daily Proton Fluxes from 2011 to 2019 Measured by the Alpha Magnetic Spectrometer on the International Space Station from 1 to 100 GV. PHYSICAL REVIEW LETTERS 2021; 127:271102. [PMID: 35061443 DOI: 10.1103/physrevlett.127.271102] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/19/2021] [Revised: 09/24/2021] [Accepted: 11/08/2021] [Indexed: 06/14/2023]
Abstract
We present the precision measurement of the daily proton fluxes in cosmic rays from May 20, 2011 to October 29, 2019 (a total of 2824 days or 114 Bartels rotations) in the rigidity interval from 1 to 100 GV based on 5.5×10^{9} protons collected with the Alpha Magnetic Spectrometer aboard the International Space Station. The proton fluxes exhibit variations on multiple timescales. From 2014 to 2018, we observed recurrent flux variations with a period of 27 days. Shorter periods of 9 days and 13.5 days are observed in 2016. The strength of all three periodicities changes with time and rigidity. The rigidity dependence of the 27-day periodicity is different from the rigidity dependences of 9-day and 13.5-day periods. Unexpectedly, the strength of 9-day and 13.5-day periodicities increases with increasing rigidities up to ∼10 GV and ∼20 GV, respectively. Then the strength of the periodicities decreases with increasing rigidity up to 100 GV.
Collapse
|
27
|
Wang C, Liu J, Peng X, Li J, Yang Y, Han Y, Xu J, Hong B, Gong J, Ge H, Wang X. FeSiCrB amorphous soft magnetic composites filled with Co2Z hexaferrites for enhanced effective permeability. ADV POWDER TECHNOL 2021. [DOI: 10.1016/j.apt.2021.11.030] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
28
|
Gong J, Drobni ZD, Zafar A, Quinaglia T, Hartmann SE, Gilman HK, Raghu VK, Gongora C, Alvi R, Zubiri L, Nohria A, Sullivan RJ, Reynolds KL, Zlotoff DA, Neilan TG. Pericardial disease in patients treated with immune checkpoint inhibitors. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.1833] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
There are limited data on the occurrence, associations and outcomes of pericardial effusions and pericarditis after treatment with immune checkpoint inhibitors (ICIs).
Purpose
To evaluate incidence of pericardial disease in patients treated with an ICI.
Methods
This was a retrospective study at a single academic center that compared 2842 consecutive patients who received ICIs with 2699 age- and cancer-type matched patients with metastatic disease who did not receive ICI (design 1). A pericardial event was defined as a composite outcome of pericarditis and new or worsening moderate or large pericardial effusion. The endpoints were obtained through chart review and were blindly adjudicated. To identify risk factors associated with a pericardial event, in a second analysis, we also compared patients who developed an event on an ICI to patients treated with an ICI who did not develop a pericardial event (design 2). Cox proportional hazard model and logistical regression analysis were performed to study the association between ICI use and pericardial disease as well as pericardial disease and mortality. An additional 6-week landmark analysis was performed to account for lead-time bias.
Results
There were 42 pericardial events in the patients treated with ICI (n=2842) over 193 days (interquartile range 64 to 411) with an incidence rate of 1.57 events per 100 person-years. There was a 4-fold increase in the risk for pericarditis or a pericardial effusion among patients on an ICI compared to controls not treated with ICI after adjusting for potential confounders (hazard ratio [HR] 4.37, 95% confidence interval [CI] 2.09–9.14, p<0.001). Patients who developed pericardial disease while on an ICI had a trend for increased all-cause mortality (HR 1.53, 95% CI 0.99–2.36, p=0.05) compared to those who did not develop pericardial disease. When comparing those who developed pericardial disease after ICI treatment to those who did not, a higher dose of corticosteroid pre-ICI (>0.7 mg/kg prednisone) was associated with increased risk of pericardial disease (HR 2.56, 95% CI 1.00–6.57, p=0.049).
Conclusions
ICI use was associated with an increased risk for development of pericardial disease among cancer patients and a pericardial event on an ICI was associated with a trend towards increased mortality.
Funding Acknowledgement
Type of funding sources: Public Institution(s). Main funding source(s): National Institutes of Health/National Heart, Lung, and Blood Institute; a gift from A. Curt Greer and Pamela Kohlberg
Collapse
|
29
|
Aguilar M, Cavasonza LA, Alpat B, Ambrosi G, Arruda L, Attig N, Barao F, Barrin L, Bartoloni A, Başeğmez-du Pree S, Battiston R, Behlmann M, Beranek B, Berdugo J, Bertucci B, Bindi V, Bollweg K, Borgia B, Boschini MJ, Bourquin M, Bueno EF, Burger J, Burger WJ, Burmeister S, Cai XD, Capell M, Casaus J, Castellini G, Cervelli F, Chang YH, Chen GM, Chen GR, Chen HS, Chen Y, Cheng L, Chou HY, Chouridou S, Choutko V, Chung CH, Clark C, Coignet G, Consolandi C, Contin A, Corti C, Cui Z, Dadzie K, Delgado C, Della Torre S, Demirköz MB, Derome L, Di Falco S, Di Felice V, Díaz C, Dimiccoli F, von Doetinchem P, Dong F, Donnini F, Duranti M, Egorov A, Eline A, Feng J, Fiandrini E, Fisher P, Formato V, Freeman C, Gámez C, García-López RJ, Gargiulo C, Gast H, Gervasi M, Giovacchini F, Gómez-Coral DM, Gong J, Goy C, Grabski V, Grandi D, Graziani M, Haino S, Han KC, Hashmani RK, He ZH, Heber B, Hsieh TH, Hu JY, Incagli M, Jang WY, Jia Y, Jinchi H, Khiali B, Kim GN, Kirn T, Konyushikhin M, Kounina O, Kounine A, Koutsenko V, Krasnopevtsev D, Kuhlman A, Kulemzin A, La Vacca G, Laudi E, Laurenti G, Lazzizzera I, Lebedev A, Lee HT, Lee SC, Li JQ, Li M, Li Q, Li S, Li JH, Li ZH, Liang J, Light C, Lin CH, Lippert T, Liu JH, Liu Z, Lu SQ, Lu YS, Luebelsmeyer K, Luo JZ, Luo X, Machate F, Mañá C, Marín J, Marquardt J, Martin T, Martínez G, Masi N, Maurin D, Medvedeva T, Menchaca-Rocha A, Meng Q, Mikhailov VV, Molero M, Mott P, Mussolin L, Negrete J, Nikonov N, Nozzoli F, Oliva A, Orcinha M, Palermo M, Palmonari F, Paniccia M, Pashnin A, Pauluzzi M, Pensotti S, Phan HD, Plyaskin V, Pohl M, Poluianov S, Qin X, Qu ZY, Quadrani L, Rancoita PG, Rapin D, Conde AR, Robyn E, Rosier-Lees S, Rozhkov A, Rozza D, Sagdeev R, Schael S, von Dratzig AS, Schwering G, Seo ES, Shakfa Z, Shan BS, Siedenburg T, Solano C, Song JW, Song XJ, Sonnabend R, Strigari L, Su T, Sun Q, Sun ZT, Tacconi M, Tang XW, Tang ZC, Tian J, Ting SCC, Ting SM, Tomassetti N, Torsti J, Tüysüz C, Urban T, Usoskin I, Vagelli V, Vainio R, Valencia-Otero M, Valente E, Valtonen E, Vázquez Acosta M, Vecchi M, Velasco M, Vialle JP, Wang CX, Wang L, Wang LQ, Wang NH, Wang QL, Wang S, Wang X, Wang Y, Wang ZM, Wei J, Weng ZL, Wu H, Xiong RQ, Xu W, Yan Q, Yang Y, Yashin II, Yi H, Yu YM, Yu ZQ, Zannoni M, Zhang C, Zhang F, Zhang FZ, Zhang JH, Zhang Z, Zhao F, Zheng C, Zheng ZM, Zhuang HL, Zhukov V, Zichichi A, Zuccon P. Erratum: Properties of a New Group of Cosmic Nuclei: Results from the Alpha Magnetic Spectrometer on Sodium, Aluminum, and Nitrogen [Phys. Rev. Lett. 127, 021101 (2021)]. PHYSICAL REVIEW LETTERS 2021; 127:159901. [PMID: 34678040 DOI: 10.1103/physrevlett.127.159901] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/23/2021] [Indexed: 06/13/2023]
Abstract
This corrects the article DOI: 10.1103/PhysRevLett.127.021101.
Collapse
|
30
|
Pang H, Lv J, Xu T, Li Z, Gong J, Liu Q, Wang Y, Wang J, Xia Z, Li Z, Li L, Zhu L. Incidence and risk factors of female urinary incontinence: a 4-year longitudinal study among 24 985 adult women in China. BJOG 2021; 129:580-589. [PMID: 34536320 PMCID: PMC9298368 DOI: 10.1111/1471-0528.16936] [Citation(s) in RCA: 22] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2021] [Revised: 06/05/2021] [Accepted: 06/25/2021] [Indexed: 11/30/2022]
Abstract
OBJECTIVE To estimate the incidence of urinary incontinence (UI), including its subtypes stress UI (SUI), urgency UI (UUI) and mixed UI (MUI), and to examine risk factors for de novo SUI and UUI in Chinese women. DESIGN Nationwide longitudinal study. SETTING Six geographic regions of China. PARTICIPANTS Women aged ≥20 years old were included using a multistage, stratified, cluster sampling method. METHODS This study was conducted between May 2014 and March 2016, with follow up in 2018. Data on demographics, medical history, lifestyle and physiological and anthropometric information were collected. MAIN OUTCOME MEASUREMENTS Incidence, rate ratio (RR). RESULTS Analyses included 24 985 women (mean age 41.9 years).The follow-up response rate was 55.5%, median follow-up time was 3.7 years. The standardised incidences of UI, SUI, UUI and MUI were 21.2, 13.1, 3.0 and 5.1 per 1000 person-years, respectively. Risk factors for de novo SUI included delivery pattern (vaginal spontaneous delivery RR 2.12, 95% CI 1.62-2.78 and instrumental delivery RR 3.30, 95% CI 1.99-5.45), high body mass index (BMI) (overweight RR 1.52, 95% CI 1.33-1.74 and obesity RR 1.67, 95% CI 1.32-2.11), cigarette smoking (RR 1.54, 95% CI 1.12-2.12), chronic cough (RR 1.44, 95% CI 1.17-1.76), diabetes (RR 1.33, 95% CI 1.10-1.60) and older age (50-59 years RR 1.49, 95% CI 1.16-1.90 and 60-69 years RR 1.61, 95% CI 1.22-2.13).The risk factors significantly associated with de novo UUI were age (RR increased from 1.21, 95% CI 0.74-1.99, at 30-39 years to 6.3, 95% CI 3.85-10.30, at >70 years) and diabetes (RR 1.48, 95% CI 1.05-2.09). CONCLUSIONS The incidence of female UI is 21.2 per 1000 person-years in China. Delivery (vaginal spontaneous delivery, instrumental delivery), high BMI, cigarette smoking, chronic cough, diabetes and older age were risk factors. TWEETABLE ABSTRACT The incidence of female urinary incontinence was 21.2 per 1000 person-years in China. Delivery, BMI, diabetes and old age are risk factors.
Collapse
|
31
|
Qi C, Qin Y, Liu D, Gong J, Ge S, Zhang M, Peng Z, Zhou J, Zhang X, Peng X, Wang H, He C, Xiao J, Li Z, Shen L. 1372O CLDN 18.2-targeted CAR-T cell therapy in patients with cancers of the digestive system. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1481] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
32
|
Gong J, Shen L, Luo S, Dong Z, Liu D, An S, Xu J, Yang J, Qi Y, Men J, Kong L, Yang Y, Xu T. 1377P Preliminary efficacy and safety results of KN026 (a HER2-targeted bispecific antibody) in combination with KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) in patients (pts) with HER2-positive gastrointestinal tumors. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1486] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
33
|
Aguilar M, Cavasonza LA, Alpat B, Ambrosi G, Arruda L, Attig N, Barao F, Barrin L, Bartoloni A, Başeğmez-du Pree S, Battiston R, Behlmann M, Beranek B, Berdugo J, Bertucci B, Bindi V, Bollweg K, Borgia B, Boschini MJ, Bourquin M, Bueno EF, Burger J, Burger WJ, Burmeister S, Cai XD, Capell M, Casaus J, Castellini G, Cervelli F, Chang YH, Chen GM, Chen GR, Chen HS, Chen Y, Cheng L, Chou HY, Chouridou S, Choutko V, Chung CH, Clark C, Coignet G, Consolandi C, Contin A, Corti C, Cui Z, Dadzie K, Delgado C, Della Torre S, Demirköz MB, Derome L, Di Falco S, Di Felice V, Díaz C, Dimiccoli F, von Doetinchem P, Dong F, Donnini F, Duranti M, Egorov A, Eline A, Feng J, Fiandrini E, Fisher P, Formato V, Freeman C, Gámez C, García-López RJ, Gargiulo C, Gast H, Gervasi M, Giovacchini F, Gómez-Coral DM, Gong J, Goy C, Grabski V, Grandi D, Graziani M, Haino S, Han KC, Hashmani RK, He ZH, Heber B, Hsieh TH, Hu JY, Incagli M, Jang WY, Jia Y, Jinchi H, Khiali B, Kim GN, Kirn T, Konyushikhin M, Kounina O, Kounine A, Koutsenko V, Krasnopevtsev D, Kuhlman A, Kulemzin A, La Vacca G, Laudi E, Laurenti G, Lazzizzera I, Lebedev A, Lee HT, Lee SC, Li JQ, Li M, Li Q, Li S, Li JH, Li ZH, Liang J, Light C, Lin CH, Lippert T, Liu JH, Liu Z, Lu SQ, Lu YS, Luebelsmeyer K, Luo JZ, Luo X, Machate F, Mañá C, Marín J, Marquardt J, Martin T, Martínez G, Masi N, Maurin D, Medvedeva T, Menchaca-Rocha A, Meng Q, Mikhailov VV, Molero M, Mott P, Mussolin L, Negrete J, Nikonov N, Nozzoli F, Oliva A, Orcinha M, Palermo M, Palmonari F, Paniccia M, Pashnin A, Pauluzzi M, Pensotti S, Phan HD, Plyaskin V, Pohl M, Poluianov S, Qin X, Qu ZY, Quadrani L, Rancoita PG, Rapin D, Conde AR, Robyn E, Rosier-Lees S, Rozhkov A, Rozza D, Sagdeev R, Schael S, von Dratzig AS, Schwering G, Seo ES, Shakfa Z, Shan BS, Siedenburg T, Solano C, Song JW, Song XJ, Sonnabend R, Strigari L, Su T, Sun Q, Sun ZT, Tacconi M, Tang XW, Tang ZC, Tian J, Ting SCC, Ting SM, Tomassetti N, Torsti J, Tüysüz C, Urban T, Usoskin I, Vagelli V, Vainio R, Valencia-Otero M, Valente E, Valtonen E, Vázquez Acosta M, Vecchi M, Velasco M, Vialle JP, Wang CX, Wang L, Wang LQ, Wang NH, Wang QL, Wang S, Wang X, Wang Y, Wang ZM, Wei J, Weng ZL, Wu H, Xiong RQ, Xu W, Yan Q, Yang Y, Yashin II, Yi H, Yu YM, Yu ZQ, Zannoni M, Zhang C, Zhang F, Zhang FZ, Zhang JH, Zhang Z, Zhao F, Zheng C, Zheng ZM, Zhuang HL, Zhukov V, Zichichi A, Zuccon P. Properties of a New Group of Cosmic Nuclei: Results from the Alpha Magnetic Spectrometer on Sodium, Aluminum, and Nitrogen. PHYSICAL REVIEW LETTERS 2021; 127:021101. [PMID: 34296911 DOI: 10.1103/physrevlett.127.021101] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/03/2021] [Revised: 04/30/2021] [Accepted: 06/01/2021] [Indexed: 06/13/2023]
Abstract
We report the properties of sodium (Na) and aluminum (Al) cosmic rays in the rigidity range 2.15 GV to 3.0 TV based on 0.46 million sodium and 0.51 million aluminum nuclei collected by the Alpha Magnetic Spectrometer experiment on the International Space Station. We found that Na and Al, together with nitrogen (N), belong to a distinct cosmic ray group. In this group, we observe that, similar to the N flux, both the Na flux and Al flux are well described by the sums of a primary cosmic ray component (proportional to the silicon flux) and a secondary cosmic ray component (proportional to the fluorine flux). The fraction of the primary component increases with rigidity for the N, Na, and Al fluxes and becomes dominant at the highest rigidities. The Na/Si and Al/Si abundance ratios at the source, 0.036±0.003 for Na/Si and 0.103±0.004 for Al/Si, are determined independent of cosmic ray propagation.
Collapse
|
34
|
Hu J, Wang Q, Zeng Y, Xu M, Gong J, Yang J. The impact of ultrasound-guided transmuscular quadratus lumborum block combined with local infiltration analgesia for arthroplasty on postoperative pain relief. J Clin Anesth 2021; 73:110372. [PMID: 34098394 DOI: 10.1016/j.jclinane.2021.110372] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2021] [Revised: 05/14/2021] [Accepted: 05/22/2021] [Indexed: 02/08/2023]
Abstract
STUDY OBJECTIVE This study aimed to evaluate the efficacy of ultrasound-guided transmuscular quadratus lumborum block (QLB) combined with local infiltration analgesia (LIA) for pain management and recovery in patients who have undergone total hip arthroplasty (THA) via a posterolateral approach. DESIGN This was a prospective, randomized controlled trial. SETTING We collected data in the preoperative area, operating room, and bed ward. PATIENTS A total of 80 patients with American Society of Anesthesiology functional status scores of II-III were included and assigned to two groups, and all 80 patients were included in the final analysis. INTERVENTIONS All included patients were randomly assigned to the nerve block (group N) or the control group (group C). Patients in the group N received transmuscular QLB combined with LIA, while patients in the group C received only LIA. MEASUREMENTS The primary outcome was postoperative pain during the first active motion: it was measured at six hours after surgery and assessed using a visual analog scale (VAS). Secondary outcomes were the resting VAS scores in the post-anesthesia care unit (PACU) and at 2, 6, 12, 24, 48, and 72 h after surgery; VAS scores during motion at 12, 24, 48, and 72 h after surgery; intraoperative consumption of opioids; postoperative consumption of morphine hydrochloride; frequency of sleep interruption due to pain on the night of surgery; time until the first "walk out of the bed" after surgery; muscle strength of the quadriceps femoris; and postoperative adverse effects. MAIN RESULTS Compared to the group C, patients in the group N had significantly lower VAS scores during motion at 6, 12, and 24 h after surgery, as well as lower resting VAS scores in the PACU and at 2, 6, 12, and 24 h after surgery. Patients in the group N also consumed significantly smaller amounts of intraoperative opioids and morphine after surgery. Patients in the group N reported significantly fewer interruptions in sleep due to pain on the night of surgery and were able to "walk out of the bed" significantly earlier than those in the group C. There was no significant difference between the two groups in muscle strength of the quadriceps femoris or incidence of postoperative adverse effects. CONCLUSIONS Compared to treatment with LIA alone, ultrasound-guided transmuscular QLB combined with LIA can provide better postoperative pain relief and enhance the recovery of THA patients, since it does not cause quadriceps femoris muscle weakness and is associated with significantly lower need for intraoperative opioids.
Collapse
|
35
|
Cao D, Chu L, Xu Z, Gong J, Deng R, Wang B, Zhou S. Visfatin facilitates gastric cancer malignancy by targeting snai1 via the NF-κB signaling. Hum Exp Toxicol 2021; 40:1646-1655. [PMID: 33823623 DOI: 10.1177/09603271211006168] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
BACKGROUND Visfatin acts as an oncogenic factor in numerous tumors through a variety of cellular processes. Visfatin has been revealed to promote cell migration and invasion in gastric cancer (GC). Snai1 is a well-known regulator of EMT process in cancers. However, the relationship between visfatin and snai1 in GC remains unclear. The current study aimed to explore the role of visfatin in GC. METHODS The RT-qPCR and western blot analysis were used to measure RNA and protein levels, respectively. The cell migration and invasion were tested by Trans-well assays and western blot analysis. RESULTS Visfatin showed upregulation in GC cells. Additionally, Visfatin with increasing concentration facilitated epithelial-mesenchymal transition (EMT) process by increasing E-cadherin and reducing N-cadherin and Vimentin protein levels in GC cells. Moreover, endogenous overexpression and knockdown of visfatin promoted and inhibited migratory and invasive abilities of GC cells, respectively. Then, we found that snai1 protein level was positively regulated by visfatin in GC cells. In addition, visfatin activated the NF-κB signaling to modulate snai1 protein expression. Furthermore, the silencing of snai1 counteracted the promotive impact of visfatin on cell migration, invasion and EMT process in GC. CONCLUSION Visfatin facilitates cell migration, invasion and EMT process by targeting snai1 via the NF-κB signaling, which provides a potential insight for the treatment of GC.
Collapse
|
36
|
Pang H, Zhang L, Han S, Li Z, Gong J, Liu Q, Liu X, Wang J, Xia Z, Lang J, Xu T, Zhu L. A nationwide population-based survey on the prevalence and risk factors of symptomatic pelvic organ prolapse in adult women in China - a pelvic organ prolapse quantification system-based study. BJOG 2021; 128:1313-1323. [PMID: 33619817 PMCID: PMC8252658 DOI: 10.1111/1471-0528.16675] [Citation(s) in RCA: 29] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2020] [Accepted: 02/19/2021] [Indexed: 01/22/2023]
Abstract
Objective To determine the prevalence, risk factors and burden of symptomatic pelvic organ prolapse (POP) in adult Chinese women. Design A nationwide cross‐sectional study. Setting Six geographic regions of mainland China. Participants Women aged ≥20 years old were included using a multistage, stratified, cluster sampling method from February 2014 through March 2016. Methods We conducted a nationwide epidemiological survey. ‘Symptomatic POP’ was determined by a screening questionnaire and physical examination. Main outcome measurements Prevalence, odds ratio (OR). Results A total of 55 477 women (response rate, 92.5%; mean age, 45.1 years old) were included. The prevalence of symptomatic POP was 9.6% (95% CI 9.3–9.8%) and it increased with age in each stage (P < 0.05). Symptomatic POP‐Q stage II, which mainly involved anterior compartment prolapse, was the most common (7.52%). Minor/moderate burden of symptomatic POP was the most common, with a prevalence of 9.7% (95% CI 9.5–10.0%). The odds for each type of symptomatic POP increased with age (>50 vs 20‐29 years old in symptomatic POP‐Q stage II or higher, OR increased from 1.34 [95% CI 1.32–1.45] to 7.34 [95% CI 4.34–12.41]) and multiple vaginal deliveries (multiparous [≥3] vs nulliparous in symptomatic POP‐Q stage II or higher, OR increased from 1.91 [1.71–2.13] to 2.78 [2.13–3.64]). Conclusions We found a lower prevalence of symptomatic POP than that found in other surveys. The main type of symptomatic POP was anterior compartment prolapse, indicating that it should be considered first. Older age and multiple vaginal deliveries increased the odds of each type of symptomatic POP. Tweetable abstract The prevalence of female symptomatic pelvic organ prolapse (POP) was 9.6% in China. It is related to old age and multiple vaginal deliveries. The prevalence of female symptomatic pelvic organ prolapse (POP) was 9.6% in China. It is related to old age and multiple vaginal deliveries.
Collapse
|
37
|
Zheng LM, Gong J, Zou Y, Zhang MN, Yu TP, Hou J, Zhou Q, Chen N. [Epithelioid glioblastoma with BRAF V600E mutation: a clinicopathological and molecular study]. ZHONGHUA BING LI XUE ZA ZHI = CHINESE JOURNAL OF PATHOLOGY 2021; 50:229-235. [PMID: 33677887 DOI: 10.3760/cma.j.cn112151-20200617-00479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Objective: To investigate the clinicopathological and molecular characteristics of the epithelioid glioblastoma (eGBM) with BRAF V600E mutation. Methods: Sixteen cases of eGBM with BRAF V600E mutation diagnosed at the West China Hospital of Sichuan University, China from 2012 to 2019 were collected. Their clinicopathological and molecular characteristics were analyzed. Results: The range of patients' age was from 7 to 61 years (median 31.5 years). There were 4 males and 12 females, with a male to female ratio of 1∶3. Eleven cases were newly diagnosed eGBM and five cases had a previous history of astrocytomas. Most of the tumors were located in the cerebral hemisphere, often in the frontal lobe, with an average diameter of 4.6 cm (2.0-8.0 cm). The tumors were composed of relatively uniform, closely packed epithelioid cells, some showing discohesion, with distinct cell membrane, eosinophilic cytoplasm, eccentric nuclei, distinct nucleoli and mitotic activity. Palisaded/coagulative necrosis was seen in all cases. Glomerular microvascular proliferation was seen in most of the cases, while mono-or multi-nucleated tumor giant cells were seen in some cases. Focal sarcomatoid area was seen in 2 cases, and focal pleomorphic xanthoastrocytoma (PXA)-like area was seen in 3 cases. Immunohistochemistry showed variable positivity for GFAP, Olig2 and p53. The median Ki-67 index was 30% (10%-50%). Only one case lost ATRX protein expression. Sanger sequencing identified the BRAF V600E mutation in all sixteen patients. Five cases also had mutations in the TERT gene promoter. No IDH1 (R132) or IDH2 (R172) mutation was detected. Surgical resection of the tumors was performed for all patients, and 3 patients also received adjuvant radiotherapy and chemotherapy. Follow-up data were available for 15 patients, with a follow-up time of 1-89 months (median 10 months). Among the 15 patients, 7 patients died of disease and another 5 patients had recurrences. The overall survival time of the patients under 35 years of age was significantly longer than that of the patients aged 35 years or older (P=0.014), but their progression-free survival was not statistically different (P=0.232). Conclusions: eGBM with BRAF V600E mutation is more commonly detected in young women than other the populations (i.e. elderly or male). The epithelioid morphology should include rhabdoid meningioma, anaplastic PXA, atypical teratoid/rhabdoid tumor, metastatic tumors, and melanoma in its differential diagnosis. PXA-like area is observed in some eGBM cases, suggesting a relationship of these two types of tumor. eGBM is a high-grade malignant tumor and most of the cases show recurrences or deaths in a short-period time. The younger patients have a relatively better prognosis than the older ones.
Collapse
|
38
|
Liu C, Gong J, Yu H, Liu Q, Wang S, Wang J. P78.02 A CT-Based Radiomics Approach to Predict Nivolumab Response in Advanced Non–Small-Cell Lung Cancer. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.1165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
39
|
Tan Z, Lu P, Adewole D, Diarra M, Gong J, Yang C. Iron requirement in the infection of Salmonella and its relevance to poultry health. J APPL POULTRY RES 2021. [DOI: 10.1016/j.japr.2020.09.016] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
|
40
|
Aguilar M, Cavasonza LA, Allen MS, Alpat B, Ambrosi G, Arruda L, Attig N, Barao F, Barrin L, Bartoloni A, Başeğmez-du Pree S, Battiston R, Behlmann M, Beranek B, Berdugo J, Bertucci B, Bindi V, Bollweg K, Borgia B, Boschini MJ, Bourquin M, Bueno EF, Burger J, Burger WJ, Burmeister S, Cai XD, Capell M, Casaus J, Castellini G, Cervelli F, Chang YH, Chen GM, Chen GR, Chen HS, Chen Y, Cheng L, Chou HY, Chouridou S, Choutko V, Chung CH, Clark C, Coignet G, Consolandi C, Contin A, Corti C, Cui Z, Dadzie K, Delgado C, Della Torre S, Demirköz MB, Derome L, Di Falco S, Di Felice V, Díaz C, Dimiccoli F, von Doetinchem P, Dong F, Donnini F, Duranti M, Egorov A, Eline A, Feng J, Fiandrini E, Fisher P, Formato V, Freeman C, Galaktionov Y, Gámez C, García-López RJ, Gargiulo C, Gast H, Gervasi M, Giovacchini F, Gómez-Coral DM, Gong J, Goy C, Grabski V, Grandi D, Graziani M, Haino S, Han KC, Hashmani RK, He ZH, Heber B, Hsieh TH, Hu JY, Incagli M, Jang WY, Jia Y, Jinchi H, Kanishev K, Khiali B, Kim GN, Kirn T, Konyushikhin M, Kounina O, Kounine A, Koutsenko V, Kuhlman A, Kulemzin A, La Vacca G, Laudi E, Laurenti G, Lazzizzera I, Lebedev A, Lee HT, Lee SC, Li JQ, Li M, Li Q, Li S, Li JH, Li ZH, Liang J, Light C, Lin CH, Lippert T, Liu JH, Liu Z, Lu SQ, Lu YS, Luebelsmeyer K, Luo JZ, Luo X, Lyu SS, Machate F, Mañá C, Marín J, Marquardt J, Martin T, Martínez G, Masi N, Maurin D, Menchaca-Rocha A, Meng Q, Mikhailov VV, Mo DC, Molero M, Mott P, Mussolin L, Negrete J, Nikonov N, Nozzoli F, Oliva A, Orcinha M, Palermo M, Palmonari F, Paniccia M, Pashnin A, Pauluzzi M, Pensotti S, Phan HD, Piandani R, Plyaskin V, Poluianov S, Qin X, Qu ZY, Quadrani L, Rancoita PG, Rapin D, Conde AR, Robyn E, Rosier-Lees S, Rozhkov A, Rozza D, Sagdeev R, Schael S, Schulz von Dratzig A, Schwering G, Seo ES, Shakfa Z, Shan BS, Siedenburg T, Solano C, Song JW, Song XJ, Sonnabend R, Strigari L, Su T, Sun Q, Sun ZT, Tacconi M, Tang XW, Tang ZC, Tian J, Ting SCC, Ting SM, Tomassetti N, Torsti J, Tüysüz C, Urban T, Usoskin I, Vagelli V, Vainio R, Valencia-Otero M, Valente E, Valtonen E, Vázquez Acosta M, Vecchi M, Velasco M, Vialle JP, Wang CX, Wang L, Wang LQ, Wang NH, Wang QL, Wang S, Wang X, Wang Y, Wang ZM, Wei J, Weng ZL, Wu H, Xiong RQ, Xu W, Yan Q, Yang Y, Yashin II, Yi H, Yu YM, Yu ZQ, Zannoni M, Zhang C, Zhang F, Zhang FZ, Zhang JH, Zhang Z, Zhao F, Zheng C, Zheng ZM, Zhuang HL, Zhukov V, Zichichi A, Zuccon P. Properties of Heavy Secondary Fluorine Cosmic Rays: Results from the Alpha Magnetic Spectrometer. PHYSICAL REVIEW LETTERS 2021; 126:081102. [PMID: 33709764 DOI: 10.1103/physrevlett.126.081102] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/20/2020] [Accepted: 01/22/2021] [Indexed: 06/12/2023]
Abstract
Precise knowledge of the charge and rigidity dependence of the secondary cosmic ray fluxes and the secondary-to-primary flux ratios is essential in the understanding of cosmic ray propagation. We report the properties of heavy secondary cosmic ray fluorine F in the rigidity R range 2.15 GV to 2.9 TV based on 0.29 million events collected by the Alpha Magnetic Spectrometer experiment on the International Space Station. The fluorine spectrum deviates from a single power law above 200 GV. The heavier secondary-to-primary F/Si flux ratio rigidity dependence is distinctly different from the lighter B/O (or B/C) rigidity dependence. In particular, above 10 GV, the F/Si/B/O ratio can be described by a power law R^{δ} with δ=0.052±0.007. This shows that the propagation properties of heavy cosmic rays, from F to Si, are different from those of light cosmic rays, from He to O, and that the secondary cosmic rays have two classes.
Collapse
|
41
|
Gong J, Wang Y, Shu C. LncRNA CHRF promotes cell invasion and migration via EMT in gastric cancer. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES 2021; 24:1168-1176. [PMID: 32096147 DOI: 10.26355/eurrev_202002_20168] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE Long non-coding RNAs (lncRNAs) have been verified to involve in the development and progression of gastric cancer (GC). However, the expression of lncRNA CHRF level in GC has not been mentioned before. Here, we focused on the function of lncRNA CHRF played in GC. PATIENTS AND METHODS A total of 103 GC tissues and paired para-tumor tissues from GC patients were collected. The quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) was applied to measure the lncRNA CHRF level in these samples and GC cell lines. The Wound-healing experiment, transwell assay, and Matrigel assay were employed to study the migration and invasion abilities of GC cells. The underlying molecular of lncRNA CHRF was measured using Western-blot. RESULTS LncRNA CHRF expression was significantly higher in 103 GC tissue samples compared with the adjacent para-tumor samples. In GC cells, lncRNA CHRF showed increased expression levels than the human fetal gastric epithelial cells (GES-1). Inhibition of lncRNA CHRF reduced the invasion and migration of MKN-7 cells while the over-expression of lncRNA CHRF promoted HGC-27 cells metastasis. Furthermore, we found that lncRNA CHRF could promote the progression of epithelial-mesenchymal transition (EMT) to promote the GC cell metastasis. CONCLUSIONS Our current study demonstrated that lncRNA CHRF functioned as an oncogene in GC and promoted cell invasion and migration via EMT. This might furnish a potential target for the GC biological diagnosis and therapy.
Collapse
|
42
|
Bao Z, Wang LJ, He K, Lin X, Yu T, Li J, Gong J, Xiang G. High expression of ACE2 in the human lung leads to the release of IL6 by suppressing cellular immunity: IL6 plays a key role in COVID-19. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES 2021; 25:527-540. [PMID: 33506945 DOI: 10.26355/eurrev_202101_24425] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
OBJECTIVE The pathogenesis of coronavirus disease 2019 (COVID-19) remains clear, and no effective treatment exists. SARS-CoV-2 is the virus that causes COVID-19 and uses ACE2 as a cell receptor to invade human cells. Therefore, ACE2 is a key factor to analyze the SARS-CoV-2 infection mechanism. MATERIALS AND METHODS We included 9,783 sequencing results of different organs, analyzed the effects of different ACE2 expression patterns in organs and immune regulation. RESULTS We found that ACE2 expression was significantly increased in the lungs and digestive tract. The cellular immunity of individuals with elevated ACE2 expression is activated, whereas humoral immunity is dampened, leading to the release of many inflammatory factors dominated by IL6. Furthermore, by studying the sequencing results of SARS-CoV-2-infected and uninfected cells, IL6 was found to be an indicator of a significant increase in the number of infected cells. However, although patients with high expression of ACE2 will release many inflammatory factors dominated by IL6, cellular immunity in the colorectum is significantly activated. This effect may explain why individuals with SARS-CoV-2 infection have severe lung symptoms and digestion issues, which are important causes of milder symptoms. CONCLUSIONS This finding indicates that ACE2 and IL6 inhibitors have important value in COVID-19.
Collapse
|
43
|
Aguilar M, Cavasonza LA, Allen MS, Alpat B, Ambrosi G, Arruda L, Attig N, Barao F, Barrin L, Bartoloni A, Başeğmez-du Pree S, Battiston R, Behlmann M, Beischer B, Berdugo J, Bertucci B, Bindi V, de Boer W, Bollweg K, Borgia B, Boschini MJ, Bourquin M, Bueno EF, Burger J, Burger WJ, Burmeister S, Cai XD, Capell M, Casaus J, Castellini G, Cervelli F, Chang YH, Chen GM, Chen GR, Chen HS, Chen Y, Cheng L, Chou HY, Chouridou S, Choutko V, Chung CH, Clark C, Coignet G, Consolandi C, Contin A, Corti C, Cui Z, Dadzie K, Delgado C, Della Torre S, Demirköz MB, Derome L, Di Falco S, Di Felice V, Díaz C, Dimiccoli F, von Doetinchem P, Dong F, Donnini F, Duranti M, Egorov A, Eline A, Feng J, Fiandrini E, Fisher P, Formato V, Freeman C, Galaktionov Y, Gámez C, García-López RJ, Gargiulo C, Gast H, Gervasi M, Giovacchini F, Gómez-Coral DM, Gong J, Goy C, Grabski V, Grandi D, Graziani M, Haino S, Han KC, Hashmani RK, He ZH, Heber B, Hsieh TH, Hu JY, Incagli M, Jang WY, Jia Y, Jinchi H, Kanishev K, Khiali B, Kim GN, Kirn T, Konyushikhin M, Kounina O, Kounine A, Koutsenko V, Kuhlman A, Kulemzin A, La Vacca G, Laudi E, Laurenti G, Lazzizzera I, Lebedev A, Lee HT, Lee SC, Li JQ, Li M, Li Q, Li S, Li JH, Li ZH, Liang J, Light C, Lin CH, Lippert T, Liu JH, Liu Z, Lu SQ, Lu YS, Luebelsmeyer K, Luo JZ, Luo X, Lyu SS, Machate F, Mañá C, Marín J, Marquardt J, Martin T, Martínez G, Masi N, Maurin D, Menchaca-Rocha A, Meng Q, Mikhailov VV, Mo DC, Molero M, Mott P, Mussolin L, Negrete J, Nikonov N, Nozzoli F, Oliva A, Orcinha M, Palermo M, Palmonari F, Paniccia M, Pashnin A, Pauluzzi M, Pensotti S, Phan HD, Piandani R, Plyaskin V, Poluianov S, Qin X, Qu ZY, Quadrani L, Rancoita PG, Rapin D, Conde AR, Robyn E, Rosier-Lees S, Rozhkov A, Rozza D, Sagdeev R, Schael S, von Dratzig AS, Schwering G, Seo ES, Shakfa Z, Shan BS, Siedenburg T, Solano C, Song JW, Song XJ, Sonnabend R, Strigari L, Su T, Sun Q, Sun ZT, Tacconi M, Tang XW, Tang ZC, Tian J, Ting SCC, Ting SM, Tomassetti N, Torsti J, Tüysüz C, Urban T, Usoskin I, Vagelli V, Vainio R, Valencia-Otero M, Valente E, Valtonen E, Vázquez Acosta M, Vecchi M, Velasco M, Vialle JP, Wang CX, Wang L, Wang LQ, Wang NH, Wang QL, Wang S, Wang X, Wang Y, Wang ZM, Wei J, Weng ZL, Wu H, Xiong RQ, Xu W, Yan Q, Yang Y, Yashin II, Yi H, Yu YM, Yu ZQ, Zannoni M, Zhang C, Zhang F, Zhang FZ, Zhang JH, Zhang Z, Zhao F, Zheng C, Zheng ZM, Zhuang HL, Zhukov V, Zichichi A, Zimmermann N, Zuccon P. Properties of Iron Primary Cosmic Rays: Results from the Alpha Magnetic Spectrometer. PHYSICAL REVIEW LETTERS 2021; 126:041104. [PMID: 33576661 DOI: 10.1103/physrevlett.126.041104] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/02/2020] [Revised: 11/22/2020] [Accepted: 12/09/2020] [Indexed: 06/12/2023]
Abstract
We report the observation of new properties of primary iron (Fe) cosmic rays in the rigidity range 2.65 GV to 3.0 TV with 0.62×10^{6} iron nuclei collected by the Alpha Magnetic Spectrometer experiment on the International Space Station. Above 80.5 GV the rigidity dependence of the cosmic ray Fe flux is identical to the rigidity dependence of the primary cosmic ray He, C, and O fluxes, with the Fe/O flux ratio being constant at 0.155±0.006. This shows that unexpectedly Fe and He, C, and O belong to the same class of primary cosmic rays which is different from the primary cosmic rays Ne, Mg, and Si class.
Collapse
|
44
|
Thein K, Tsimberidou A, Piha-Paul S, Janku F, Karp D, Fu S, Zarifa A, Gong J, Hong D, Yap T, Subbiah V, Pant S, Meric-Bernstam F, Naing A. 72MO Selinexor in combination with standard chemotherapy in patients with advanced solid tumours: Results of an open label, single-center, multi-arm phase Ib study. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
45
|
Dewan P, Jhund P, Anand I, Desai A, Gong J, Lefkowitz M, Pieske B, Rizkala A, Shah S, Van Veldhuisen D, Zannad F, Zile M, Solomon S, McMurray J. Effect of sacubitril/valsartan on cognitive function in patients with HFpEF: a prespecified analysis of PARAGON-HF. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.0873] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
A theoretical concern has been raised about detrimental effects of sacubitril/valsartan (sac/val) on cognitive function as neprilysin is one of many pathways involved in clearance of amyloid beta peptides from brain tissue.
Purpose
To examine effect of sac/val, compared with valsartan, on cognitive function in patients with heart failure (HF) and preserved ejection fraction (HFpEF).
Methods
In the PARAGON-HF trial, cognitive function was tested in a subgroup of patients at baseline and follow-up, using Mini-Mental State Examination [MMSE] having a maximum score of 30 (higher scores reflect better cognitive function). Change in MMSE score from baseline to 96 wks was a prespecified exploratory endpoint. Other post hoc analyses included “cognitive decline” (fall in MMSE ≥3 pts) and assessment of cognition-related adverse events (AEs).
Results
Among 2895 patients (60% of total) in PARAGON-HF with baseline MMSE measurement, mean (SD) score was 27.4 (3.0) in patients receiving sac/val (1453) and 27.4 (2.9) in patients receiving valsartan (1442). There was no difference between sac/val and valsartan in MMSE score change from baseline to wk 96: sac/val −0.02 (SE 0.07) and valsartan 0.00 (0.07); between-treatment difference −0.02 (95% CI: −0.22 to 0.18); p-value = 0.83. Cognitive decline at 96 weeks occurred in 115 of 1071 evaluable patients (10.7%) in sac/val group and 121 of 1053 patients (11.5%) in valsartan group; risk ratio 0.97 (0.75–1.26), p-value = 0.82. Cognition-related AEs were more frequent, than in PARADIGM-HF (likely as patients in PARAGON-HF were older) but, as in PARADIGM-HF, did not differ between sac/val and comparator treatment (Table).
Conclusions
Cognitive change, measured by MMSE, did not differ between treatment with sac/val & valsartan in patients with HFpEF.
Funding Acknowledgement
Type of funding source: Private company. Main funding source(s): PARAGON-HF study was funded by Novartis Pharma.
Collapse
|
46
|
Thein K, Tsimberidou A, Piha-Paul S, Janku F, Karp D, Fu S, Zarifa A, Gong J, Yap T, Hong D, Subbiah V, Pant S, Meric-Bernstam F, Naing A. 73P Selinexor in combination with carboplatin and pemetrexed (CP) in patients with advanced or metastatic solid tumors: Results of an open label, single-center, multi-arm phase Ib study. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
47
|
Thein K, Tsimberidou A, Piha-Paul S, Janku F, Karp D, Fu S, Zarifa A, Gong J, Hong D, Yap T, Subbiah V, Pant S, Meric-Bernstam F, Naing A. 565P Selinexor in combination with topotecan in patients with advanced or metastatic solid tumours: Results of an open label, single-center, multi-arm phase Ib study. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.679] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
48
|
Aguilar M, Ali Cavasonza L, Ambrosi G, Arruda L, Attig N, Barao F, Barrin L, Bartoloni A, Başeğmez-du Pree S, Battiston R, Becker U, Behlmann M, Beischer B, Berdugo J, Bertucci B, Bindi V, de Boer W, Bollweg K, Borgia B, Boschini MJ, Bourquin M, Bueno EF, Burger J, Burger WJ, Burmeister S, Cai XD, Capell M, Casaus J, Castellini G, Cervelli F, Chang YH, Chen GM, Chen HS, Chen Y, Cheng L, Chou HY, Chouridou S, Choutko V, Chung CH, Clark C, Coignet G, Consolandi C, Contin A, Corti C, Cui Z, Dadzie K, Dai YM, Delgado C, Della Torre S, Demirköz MB, Derome L, Di Falco S, Di Felice V, Díaz C, Dimiccoli F, von Doetinchem P, Dong F, Donnini F, Duranti M, Egorov A, Eline A, Feng J, Fiandrini E, Fisher P, Formato V, Freeman C, Galaktionov Y, Gámez C, García-López RJ, Gargiulo C, Gast H, Gebauer I, Gervasi M, Giovacchini F, Gómez-Coral DM, Gong J, Goy C, Grabski V, Grandi D, Graziani M, Guo KH, Haino S, Han KC, Hashmani RK, He ZH, Heber B, Hsieh TH, Hu JY, Huang ZC, Incagli M, Jang WY, Jia Y, Jinchi H, Kanishev K, Khiali B, Kim GN, Kirn T, Konyushikhin M, Kounina O, Kounine A, Koutsenko V, Kuhlman A, Kulemzin A, La Vacca G, Laudi E, Laurenti G, Lazzizzera I, Lebedev A, Lee HT, Lee SC, Li JQ, Li M, Li Q, Li S, Li TX, Li ZH, Light C, Lin CH, Lippert T, Liu Z, Lu SQ, Lu YS, Luebelsmeyer K, Luo JZ, Lyu SS, Machate F, Mañá C, Marín J, Marquardt J, Martin T, Martínez G, Masi N, Maurin D, Menchaca-Rocha A, Meng Q, Mo DC, Molero M, Mott P, Mussolin L, Ni JQ, Nikonov N, Nozzoli F, Oliva A, Orcinha M, Palermo M, Palmonari F, Paniccia M, Pashnin A, Pauluzzi M, Pensotti S, Phan HD, Piandani R, Plyaskin V, Poluianov S, Qi XM, Qin X, Qu ZY, Quadrani L, Rancoita PG, Rapin D, Reina Conde A, Rosier-Lees S, Rozhkov A, Rozza D, Sagdeev R, Schael S, Schmidt SM, Schulz von Dratzig A, Schwering G, Seo ES, Shan BS, Shi JY, Siedenburg T, Solano C, Sonnabend R, Song JW, Sun Q, Sun ZT, Tacconi M, Tang XW, Tang ZC, Tian J, Ting SCC, Ting SM, Tomassetti N, Torsti J, Tüysüz C, Urban T, Usoskin I, Vagelli V, Vainio R, Valente E, Valtonen E, Vázquez Acosta M, Vecchi M, Velasco M, Vialle JP, Wallmann C, Wang LQ, Wang NH, Wang QL, Wang S, Wang X, Wang ZX, Wei J, Weng ZL, Wu H, Xiong RQ, Xu W, Yan Q, Yang Y, Yi H, Yu YJ, Yu ZQ, Zannoni M, Zhang C, Zhang F, Zhang FZ, Zhang JH, Zhang Z, Zhao F, Zheng ZM, Zhuang HL, Zhukov V, Zichichi A, Zimmermann N, Zuccon P. Properties of Neon, Magnesium, and Silicon Primary Cosmic Rays Results from the Alpha Magnetic Spectrometer. PHYSICAL REVIEW LETTERS 2020; 124:211102. [PMID: 32530660 DOI: 10.1103/physrevlett.124.211102] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/10/2020] [Accepted: 04/20/2020] [Indexed: 06/11/2023]
Abstract
We report the observation of new properties of primary cosmic rays, neon (Ne), magnesium (Mg), and silicon (Si), measured in the rigidity range 2.15 GV to 3.0 TV with 1.8×10^{6} Ne, 2.2×10^{6} Mg, and 1.6×10^{6} Si nuclei collected by the Alpha Magnetic Spectrometer experiment on the International Space Station. The Ne and Mg spectra have identical rigidity dependence above 3.65 GV. The three spectra have identical rigidity dependence above 86.5 GV, deviate from a single power law above 200 GV, and harden in an identical way. Unexpectedly, above 86.5 GV the rigidity dependence of primary cosmic rays Ne, Mg, and Si spectra is different from the rigidity dependence of primary cosmic rays He, C, and O. This shows that the Ne, Mg, and Si and He, C, and O are two different classes of primary cosmic rays.
Collapse
|
49
|
Gong J, Bai X, Li DA, Zhao J, Li X. Prognosis Analysis of Heart Failure Based on Recurrent Attention Model. Ing Rech Biomed 2020. [DOI: 10.1016/j.irbm.2019.08.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
|
50
|
Qin W, Gong J, Zhao Y. P16 Differences in patterns of temporal variability related to different response to electroconvulsive therapy in schizophrenia. Clin Neurophysiol 2020. [DOI: 10.1016/j.clinph.2019.12.127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|